Predictors of PFS on MVA
| All patients receiving CAR-T therapy . | |||
|---|---|---|---|
| Variable . | HR . | 95% CI . | P value . |
| Age, at apheresis, y∗ | 1.0 | 0.98-1.02 | .87 |
| Female sex (yes/no) | 1.06 | 0.66-1.70 | .81 |
| Histologic subtype (de novo DLBCL/all others) | 0.94 | 0.79-1.12 | .46 |
| Non-GCB cell of origin (yes/no) | 1.07 | 0.66-1.72 | .79 |
| LDH elevation, at apheresis (yes/no) | 1.65 | 0.96-2.85 | .07 |
| IPI score, at apheresis† | 1.23 | 0.94-1.62 | .13 |
| Stage, at apheresis† | 0.91 | 0.68-1.21 | .52 |
| CNS disease, at apheresis (yes/no) | 1.28 | 0.48-3.71 | .63 |
| Prior autologous HCT (yes/no) | 1.29 | 0.74 - 2.26 | .37 |
| Number of lines pre–CAR-T∗ | 1.47 | 1.16-1.89 | <.01 |
| CAR-T construct (axi-cel/tisa-cel)‡ | 1.17 | 0.82-1.69 | .38 |
| Double hit/double expressor status (DH/DE/other) | 0.85 | 0.63-1.14 | .29 |
| BT (yes/no) | 1.72 | 1.05-2.82 | .03 |
| Days between apheresis and CAR-T∗ | 1.0 | 0.99-1.01 | .98 |
| All patients receiving CAR-T therapy . | |||
|---|---|---|---|
| Variable . | HR . | 95% CI . | P value . |
| Age, at apheresis, y∗ | 1.0 | 0.98-1.02 | .87 |
| Female sex (yes/no) | 1.06 | 0.66-1.70 | .81 |
| Histologic subtype (de novo DLBCL/all others) | 0.94 | 0.79-1.12 | .46 |
| Non-GCB cell of origin (yes/no) | 1.07 | 0.66-1.72 | .79 |
| LDH elevation, at apheresis (yes/no) | 1.65 | 0.96-2.85 | .07 |
| IPI score, at apheresis† | 1.23 | 0.94-1.62 | .13 |
| Stage, at apheresis† | 0.91 | 0.68-1.21 | .52 |
| CNS disease, at apheresis (yes/no) | 1.28 | 0.48-3.71 | .63 |
| Prior autologous HCT (yes/no) | 1.29 | 0.74 - 2.26 | .37 |
| Number of lines pre–CAR-T∗ | 1.47 | 1.16-1.89 | <.01 |
| CAR-T construct (axi-cel/tisa-cel)‡ | 1.17 | 0.82-1.69 | .38 |
| Double hit/double expressor status (DH/DE/other) | 0.85 | 0.63-1.14 | .29 |
| BT (yes/no) | 1.72 | 1.05-2.82 | .03 |
| Days between apheresis and CAR-T∗ | 1.0 | 0.99-1.01 | .98 |
| Patients receiving BT . | |||
|---|---|---|---|
| Variable (yes/no) . | HR . | 95% CI . | P value . |
| Chemotherapy-based | 5.15 | 1.55-18.25 | <.01 |
| RT§ | 1.93 | 0.49-7.94 | .35 |
| Anti-CD20 monoclonal antibody | 3.91 | 0.50-40.40 | .21 |
| Steroids alone | 2.5 | 0.53-12.63 | .25 |
| IMiD-based | 5.24 | 1.22-24.91 | .03 |
| Polatuzumab + bendamustine + rituximab | 2.14 | 0.56-8.57 | .27 |
| BTK inhibitor +/− CD20 antibody | 2.21 | 0.49-10.57 | .31 |
| Patients receiving BT . | |||
|---|---|---|---|
| Variable (yes/no) . | HR . | 95% CI . | P value . |
| Chemotherapy-based | 5.15 | 1.55-18.25 | <.01 |
| RT§ | 1.93 | 0.49-7.94 | .35 |
| Anti-CD20 monoclonal antibody | 3.91 | 0.50-40.40 | .21 |
| Steroids alone | 2.5 | 0.53-12.63 | .25 |
| IMiD-based | 5.24 | 1.22-24.91 | .03 |
| Polatuzumab + bendamustine + rituximab | 2.14 | 0.56-8.57 | .27 |
| BTK inhibitor +/− CD20 antibody | 2.21 | 0.49-10.57 | .31 |
| Patients with CAR-T failure . | |||
|---|---|---|---|
| Variable . | HR . | 95% CI . | P value . |
| Age, y∗ | 1.02 | 0.97-1.06 | .50 |
| Female sex (yes/no) | 0.63 | 0.19-1.9 | .43 |
| IPI > 1 (yes/no) | 1.42 | 0.75-2.8 | .29 |
| Stage at diagnosis† | 1.25 | 0.72-2.2 | .42 |
| Non-GCB cell of origin (yes/no) | 2.94 | 0.97-10.1 | .07 |
| Elevated LDH at apheresis (yes/no) | 0.63 | 0.18-2.2 | .47 |
| >2 lines of therapy pre–CAR-T (yes/no) | 1.89 | 1.1-3.5 | .03 |
| Double hit/double expressor status (DH/DE/other) | 0.42 | 0.18-0.89 | .03 |
| CNS involvement (yes/no) | 0.18 | 0.02-1.5 | .11 |
| Prior autologous HCT (yes/no) | 0.70 | 0.2-2.6 | .58 |
| Extranodal disease at apheresis (yes/no) | 0.68 | 0.17-2.5 | .57 |
| CAR-T construct (axi-cel/tisa-cel) | 1.75 | 0.80-4.2 | .18 |
| Days between apheresis and CAR-T∗ | 1.02 | 0.99-1.06 | .34 |
| Patients with CAR-T failure . | |||
|---|---|---|---|
| Variable . | HR . | 95% CI . | P value . |
| Age, y∗ | 1.02 | 0.97-1.06 | .50 |
| Female sex (yes/no) | 0.63 | 0.19-1.9 | .43 |
| IPI > 1 (yes/no) | 1.42 | 0.75-2.8 | .29 |
| Stage at diagnosis† | 1.25 | 0.72-2.2 | .42 |
| Non-GCB cell of origin (yes/no) | 2.94 | 0.97-10.1 | .07 |
| Elevated LDH at apheresis (yes/no) | 0.63 | 0.18-2.2 | .47 |
| >2 lines of therapy pre–CAR-T (yes/no) | 1.89 | 1.1-3.5 | .03 |
| Double hit/double expressor status (DH/DE/other) | 0.42 | 0.18-0.89 | .03 |
| CNS involvement (yes/no) | 0.18 | 0.02-1.5 | .11 |
| Prior autologous HCT (yes/no) | 0.70 | 0.2-2.6 | .58 |
| Extranodal disease at apheresis (yes/no) | 0.68 | 0.17-2.5 | .57 |
| CAR-T construct (axi-cel/tisa-cel) | 1.75 | 0.80-4.2 | .18 |
| Days between apheresis and CAR-T∗ | 1.02 | 0.99-1.06 | .34 |
| Patients receiving first-line therapy after CAR-T failure . | |||
|---|---|---|---|
| Variable (yes/no) . | HR . | 95% CI . | P value . |
| Chemotherapy | 1.4 | 0.15-33.9 | .78 |
| Radiation +/− steroids | 0.21 | 0.028-1.15 | .11 |
| Lenalidomide-based | 0.15 | 0.026-0.76 | .03 |
| Polatuzumab + bendamustine + rituximab | 0.097 | 0.013-0.57 | .01 |
| Checkpoint inhibitor-based | 0.26 | 0.03-2.2 | .20 |
| Patients receiving first-line therapy after CAR-T failure . | |||
|---|---|---|---|
| Variable (yes/no) . | HR . | 95% CI . | P value . |
| Chemotherapy | 1.4 | 0.15-33.9 | .78 |
| Radiation +/− steroids | 0.21 | 0.028-1.15 | .11 |
| Lenalidomide-based | 0.15 | 0.026-0.76 | .03 |
| Polatuzumab + bendamustine + rituximab | 0.097 | 0.013-0.57 | .01 |
| Checkpoint inhibitor-based | 0.26 | 0.03-2.2 | .20 |
Multivariate modeling using Cox regression was constructed using demographic and clinical variables to determine the impact of variables on survival outcomes. Significant P values are shown in boldface.
BTK, Bruton tyrosine kinase; DE, double expressor; DH, double hit.
Linear.
Ordinal.
Axi-cel vs tisa-cel only was included in the MVA owing to small sample size of liso-cel.
Two the 34 patients who received RT as bridging received steroids concurrently with their radiation.